Valuation dashboard for Relay Therapeutics, Inc. (RLAY) with P/E N/A, P/B 4.18, EV/EBITDA -13.85 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions.
Analysis Summary
Relay Therapeutics, Inc. reported revenue of $15.4M in the most recent fiscal year, growing at a 5-year CAGR of -28.6%.
Trailing-twelve-month margins: gross margin -5.7%, operating margin -30.0%, net margin -27.6%.
At $18.35 (closing price, October 30, 2026), RLAY has negative trailing earnings (P/E not meaningful) and an ROE of -42.27%. Market capitalisation stands at $4.0B.
Balance sheet quality for RLAY: current ratio of 22.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.18 |
| EV / EBITDA | -13.85 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.70 |
| vs Current Price | -103.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | $4.0B | 4.18 | -42.3% | |
| RVMD | Revolution Medicines, Inc. | $41.0B | 15.48 | -96.4% | |
| KYMR | Kymera Therapeutics, Inc. | $10.8B | 7.85 | -22.4% | |
| ERAS | Erasca, Inc. | $5.0B | 12.35 | -80.4% | |
| IDYA | IDEAYA Biosciences, Inc. | $3.1B | 2.45 | -16.5% | |
| TNGX | Tango Therapeutics, Inc. | $3.8B | 3.32 | -25.7% | |
| NRIX | Nurix Therapeutics, Inc. | $2.9B | 11.60 | 3.09 | 49.3% |
Price
| Price | $18.35 (closing price, October 30, 2026) |
| Market Cap | $4.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -42.27% |
| Return on Invested Capital | -33.72% |
| Return on Assets | -29.57% |
| Gross Margin | -566.59% |
| Operating Margin | -2,999.38% |
| Net Margin | -2,763.64% |
Related companies: RVMD · KYMR · ERAS · IDYA · TNGX · NRIX
Explore sector: Healthcare · Biotechnology
More sections of RLAY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks